MbrlCatalogueTitleDetail

Do you wish to reserve the book?
Diallyl trisulfide suppresses tumor growth through the attenuation of Nrf2/Akt and activation of p38/ JNK and potentiates cisplatin efficacy in gastric cancer treatment
Diallyl trisulfide suppresses tumor growth through the attenuation of Nrf2/Akt and activation of p38/ JNK and potentiates cisplatin efficacy in gastric cancer treatment
Hey, we have placed the reservation for you!
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Diallyl trisulfide suppresses tumor growth through the attenuation of Nrf2/Akt and activation of p38/ JNK and potentiates cisplatin efficacy in gastric cancer treatment
Oops! Something went wrong.
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Title added to your shelf!
Title added to your shelf!
View what I already have on My Shelf.
Oops! Something went wrong.
Oops! Something went wrong.
While trying to add the title to your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Diallyl trisulfide suppresses tumor growth through the attenuation of Nrf2/Akt and activation of p38/ JNK and potentiates cisplatin efficacy in gastric cancer treatment
Diallyl trisulfide suppresses tumor growth through the attenuation of Nrf2/Akt and activation of p38/ JNK and potentiates cisplatin efficacy in gastric cancer treatment

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
How would you like to get it?
We have requested the book for you! Sorry the robot delivery is not available at the moment
We have requested the book for you!
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Diallyl trisulfide suppresses tumor growth through the attenuation of Nrf2/Akt and activation of p38/ JNK and potentiates cisplatin efficacy in gastric cancer treatment
Diallyl trisulfide suppresses tumor growth through the attenuation of Nrf2/Akt and activation of p38/ JNK and potentiates cisplatin efficacy in gastric cancer treatment
Journal Article

Diallyl trisulfide suppresses tumor growth through the attenuation of Nrf2/Akt and activation of p38/ JNK and potentiates cisplatin efficacy in gastric cancer treatment

2017
Request Book From Autostore and Choose the Collection Method
Overview
Diallyl trisulfide (DATS), a garlic organosulfide, has shown excellent chemopreventive potential. Cisplatin (DDP) is widely used to treat solid malignant tumors, but causing serious side effects. In the current study, we attempted to elucidate the chemopreventive mechanisms of DATS in human gastric cancer BGC-823 cells in vitro, and to investigate whether DATS could enhance the anti-tumor efficacy of DDP and improve quality of life in BGC-823 xenograft mice in vivo. Treatment with DATS (25-400 pmol/L) dose-dependently inhibited the viability of BGC-823 cells in vitro with an IC5o of 115.2+4.3 pmol/L after 24 h drug exposure. DATS (50-200 pmol/L) induced cell cycle arrest at G2/M phase in BGC-823 cells, which correlated with significant accumulation of cyclin A2 and B1. DATS also induced BGC-823 cell apoptosis, which was accompanied by the modulation of Bcl-2 family members and caspase cascade activation. In BGC-823 xenograft mice, administration of DATS (20-40 mg.kg-1.d-1, ip) dose-dependently inhibited tumor growth and markedly reduced the number of Ki-67 positive cells in tumors. Interestingly, combined administration of DATS (30 mg.kg-1.d-1, ip) with DDP (5 mg/kg, every 5 d, ip) exhibited enhanced anti-tumor activity with fewer side effects. We showed that treatment of BGC-823 cells with DATS in vitro and in vivo significantly activated kinases such as p38 and JNK/MAPK and attenuated the Nrf2/Akt pathway. This study provides evidence that DATS exerts anticancer effects and enhances the antitumor efficacy of DDP, making it a novel candidate for adjuvant therapy for gastric cancer.